# An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

> **NCT00000672** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 660 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00000672
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 1993-02
- **Final completion:** —
- **Target enrollment:** 660 (—)
- **Last updated:** 2011-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000672, "An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00000672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*